NCT03107780 2025-11-13
Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
National Cancer Institute (NCI)
Ann & Robert H Lurie Children's Hospital of Chicago
Barbara Ann Karmanos Cancer Institute
Basilea Pharmaceutica
Northwestern University
Spectrum Pharmaceuticals, Inc
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Boneca Corporation